Kyverna (KYTX) news
Recent news
Kyverna Therapeutics - KYSA-8 12-month topline data expected in Q3 2026
Kyverna Therapeutics (Nasdaq: KYTX) is preparing to release 12-month topline data from its KYSA-8 Phase 2 trial of miv-cel (mivocabtagene autoleucel) in stiff person syndrome (SPS) in Q3 2026. The trial, which evaluated the safety and efficacy of miv-cel in 26 patients with SPS, previously reported…
AInvest Wire · Aug 11, 2026Kyverna Therapeutics reports pipeline progress and second quarter 2026 financial results
Kyverna Therapeutics (NASDAQ: KYTX) has reported progress in its clinical pipeline and provided an update on its financial position as of the second quarter of 2026. The company continues to advance its lead candidate, KYV-101, an autologous CD19 CAR T-cell therapy, across multiple autoimmune…
AInvest Wire · Aug 11, 2026Kyverna Therapeutics - on track to complete rolling BLA submission for MIV-CEL in SPS in Q4 2026
AInvest Wire · Jul 27, 2026Kyverna Therapeutics - Term B loan availability extended through Sept 30, 2027 if Term A fully drawn - SEC filing
AInvest Wire · Jul 9, 2026Kyverna Therapeutics - extends $15 mln term A loan availability through Dec 31, 2026 - SEC filing
AInvest Wire · Jul 9, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.